PlainPharmaWatch

CMS Open Payments · Program Year 2024

Hikma Pharmaceuticals USA

Hikma Pharmaceuticals USA reported $953,328.80 in payments to 3,664 physicians and teaching hospitals across 3,685 transactions.

See the rankings → How this is sourced
$953.3K
Total payments
3,685
Transactions
3,664
Recipients
−$6.9K
General Payments vs PY2023

Hikma Pharmaceuticals USA reported $953,328.80 in payments to 3,664 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #627 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $260.19 per recipient across 8 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Hikma Pharmaceuticals USA pairs above-median payment volume with a broadly spread payment pattern across many recipients.

#627
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
8
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Hikma Pharmaceuticals USA's CMS-reported General Payments decreased by $6.9K (−1.4%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: HIKMA PHARMACEUTICALS USAPY2023: HIKMA PHARMACEUTICALS USAPY2024: Hikma Pharmaceuticals USA. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$508.1KPY2024$501.2K
PY2023
$508,096.31
PY2024
$501,181.54

How Hikma Pharmaceuticals USA ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Hikma Pharmaceuticals USA's total vs. every reporting company

CMS Open Payments, Program Year 2024

$953,329 Top 33% higher than 67% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Hikma Pharmaceuticals USA

In Program Year 2024, Hikma Pharmaceuticals USA reported $953,328.80 in payments to 3,664 physicians and teaching hospitals across 3,685 individual transactions, an average of $258.71 per transaction and $260.19 per recipient. That total places Hikma Pharmaceuticals USA at rank #627 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 8-category general-payment breakdown below at $165.6K (17.4% of the company's reported total, 104 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 8 types of general payments, Hikma Pharmaceuticals USA's largest category was "Consulting Fee" at $165.6K - 17.4% of the company's reported total.

How Hikma Pharmaceuticals USA divides its payments

How the reported total splits across payment categories

1. Consulting Fee$165.6K2. Travel and Lodging$153.2K3. Compensation for Services…$93.0K4. Food and Beverage$66.5K5. Charitable Contribution$15.0K6. Gift$3.9K7. Honoraria$3.2K8. Education$721.00
Payment Type Amount Transactions
Consulting Fee $165.6K 104
Travel and Lodging $153.2K 58
Compensation for Services Other Than Consulting $93.0K 22
Food and Beverage $66.5K 3,343
Charitable Contribution $15.0K 1
Gift $3.9K 97
Honoraria $3.2K 3
Education $721.00 36

Recipient Concentration in General Payments

The five largest recipient relationships account for $179,640.71 (35.8%) of $501,181.54 in this company's General Payments records across 2,391 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Hikma Pharmaceuticals USA

The five named recipients with the highest reported General Payments from this company

Paul Hogya$66.1KElias Jabbour$48.7KRobert Haddad$22.1KRalph Defronzo$21.4KHagop Kantarjian$21.3K
  1. 1

    Paul Hogya

    $66,110.00 across 22 reported transactions

  2. 2

    Elias Jabbour

    $48,734.20 across 12 reported transactions

  3. 3

    Robert Haddad

    $22,052.83 across 4 reported transactions

  4. 4

    Ralph Defronzo

    $21,417.68 across 5 reported transactions

  5. 5

    Hagop Kantarjian

    $21,326.00 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $258.71. Average per recipient: $260.19.

Total Amount

$953,328.80

Avg per Transaction

$258.71

Avg per Recipient

$260.19

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Hikma Pharmaceuticals USA Share

0.0%

#627 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Hikma Pharmaceuticals USA

Almirall LLC

$946.1K 5,128 recipients

Heron Therapeutics, Inc.

$945.0K 4,695 recipients

OrganOx Ltd

$944.6K 100 recipients

Vascular Technology, Inc.

$943.2K 50 recipients

Leica Microsystems Inc.

$942.6K 487 recipients

NS Pharma, Inc.

$942.1K 369 recipients

Frequently Asked Questions

How much did Hikma Pharmaceuticals USA pay to physicians and hospitals in 2024? ▾
Hikma Pharmaceuticals USA made $953,328.80 in payments to physicians and hospitals in Program Year 2024, across 3,685 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Hikma Pharmaceuticals USA? ▾
3,664 physicians and teaching hospitals received payments from Hikma Pharmaceuticals USA in 2024, averaging $260.19 per recipient.
What types of payments did Hikma Pharmaceuticals USA make? ▾
General payments from Hikma Pharmaceuticals USA span 8 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Consulting Fee" at $165.6K, representing 17.4% of the company's reported total.
How does Hikma Pharmaceuticals USA rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Hikma Pharmaceuticals USA ranks #627 by total payment amount.
What is the average payment size from Hikma Pharmaceuticals USA? ▾
In 2024, Hikma Pharmaceuticals USA averaged $258.71 per transaction across 3,685 transactions to 3,664 recipients.
Where does the payment data for Hikma Pharmaceuticals USA come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Hikma Pharmaceuticals USA's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.